The efficacy and safety of high-intensity interval training in chemotherapy-related cardiomyopathy: Report of two cases

Hee-Eun Choi, Chul Kim, Myoung-Joo Kang, Ji-Ho Park

1Department of Rehabilitation Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea
2Department of Rehabilitation Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea
3Department of Hematology and Oncology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea

Received: September 08, 2020 Accepted: December 31, 2021 Published online: June 01, 2022

ABSTRACT

Studies suggest that exercise regimens are beneficial across all phases of cancer treatment and rehabilitation. However, studies on the efficacy and safety of cardiac rehabilitation in patients with chemotherapy-related cardiomyopathy are lacking. Herein, we present two patients diagnosed with chemotherapy-related cardiomyopathy who participated in a cardiac rehabilitation program, including eight weeks of high-intensity interval training, and their exercise capacity was monitored. Both patients showed significant increases in peak oxygen consumption and 6-min walk distance. High-intensity interval training results in objective improvements in aerobic exercise capacity without serious cardiovascular complications in patients with chemotherapy-related cardiomyopathy.

Keywords: Cardiac rehabilitation, cardiomyopathy, chemotherapy, high-intensity interval training, oxygen consumption.

The adverse effects associated with various cancer therapies have become important concerns for cancer survivors.[1] Cardio-oncology is a recently developed field aimed at significantly reducing cardiovascular morbidity and mortality and improving quality of life in cancer survivors.[2] One of the most severe complications of chemotherapy is chemotherapy-related cardiomyopathy (CRC).[3] Chemotherapy-related cardiomyopathy may appear early or late in the course of treatment and can vary from subclinical myocardial dysfunction to sudden heart failure (HF).[4] Compared with idiopathic dilated cardiomyopathy, CRC has a three-fold higher rate of mortality.[5]

Cardiac rehabilitation (CR) is a comprehensive program that includes doctor-prescribed exercises, education, or counseling about cardiac risk factors and psychosocial assessments. Cardiac rehabilitation programs have been shown to reduce the overall risk of hospitalization for recurring cardiovascular diseases and reduce cardiovascular mortality.[6] High-intensity interval training (HIIT) is one of the CR protocols that includes repeated intervals of high-intensity activity arranged between rest or low-intensity active recovery intervals.

Exercise has beneficial effects during the early and late stages of cancer therapy, as well as during rehabilitation.[1] The American Heart Association recently outlined the need for a comprehensive cardio-oncology rehabilitation model that uses a multimodal approach to prevent or alleviate cardiovascular disease and the requirement to identify high-risk cardiovascular patients, including those with cardiotoxicity associated with cancer treatment.[7]

Corresponding author: Ji-Ho Park, MD. Department of Rehabilitation Medicine, Haeundae Paik Hospital, Inje University College of Medicine, 875, Haeun-daero, Haeundae-gu, Busan, 48108, Republic of Korea.
E-mail: basis9204@hotmail.com

Cite this article as: Choi HE, Kim C, Kang MJ, Park JH. The efficacy and safety of high-intensity interval training in chemotherapy-related cardiomyopathy: Report of two cases. Turk J Phys Med Rehab 2022;68(2):290-294.

©2022 All right reserved by the Turkish Society of Physical Medicine and Rehabilitation
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes (http://creativecommons.org/licenses/by-nc/4.0/).
Recent trials have suggested that exercise training can have numerous positive effects without major adverse effects in CRC and other cardiomyopathies. However, little attention has been focused on CR protocols in patients with CRC. This case report describes improvements in exercise capacity over two months of CR with HIIT protocol in two patients with CRC.

**CASE REPORT**

Cardiac rehabilitation consisted of a cardiopulmonary exercise test (CPET), aerobic and resistance exercises, and education on cardiac risk factors. The individual exercises prescribed were based on CPET results and medical records (Table 1). The first two weeks served as an adaptation period for HIIT. The following six weeks of HIIT consisted of a 10-min warm-up at 50 to 60% of the heart rate reserve (HRR), followed by four intervals (4-min each) of walking on a treadmill (MT7; Motus, Paju-si, Korea) at 85% of the HRR with three active rest periods of 3-min walking at 50 to 60% of the HRR, and a final 10-min cool-down at 50 to 60% of the HRR. The treadmill speed and grade were constantly adjusted to. Blood pressure, HR, oxygen saturation, and electrocardiographic parameters were strictly monitored. The exercises were supervised by an experienced physical therapist and a rehabilitation medicine specialist. After the eight-week HIIT program was completed, home exercise prescriptions were provided.

**Outcome measurements**

Improvement (change from the baseline) of maximal oxygen uptake (VO$_{2\text{max}}$/kg), resting HR, maximal HR, double product (HR multiplied by systolic blood pressure), the slope of ventilatory equivalent for carbon dioxide (VE/VCO$_2$ slope), rate of perceived exertion at stage 3 of CPET, and respiratory exchange ratio at VO$_{2\text{max}}$ were utilized as CPET parameters (Table 2). We adopted improvement of left ventricular ejection fraction (LVEF) as an echocardiographic parameter and 6-min walk distance (6MWD) as a supplemental parameter of exercise capacity. In addition, the hand-grip power was measured as a parameter of upper extremity muscle strength using a JAMAR® Plus+ hand dynamometer (Performance Health, Warrenville, IL, USA).

For pulmonary function test parameters in one patient, we utilized improvement of forced vital capacity (FVC), forced expiratory volume in 1 second

| TABLE 1                                                                 |
|-------------------------------------------------------------------------|
| Characteristics of the patients                                         |
|                                                                         |
| **Case 1** | **Case 2** |                                                                         |
| Sex          | Female     | Female                      |                                                                         |
| Age (year)   | 45         | 53                          |                                                                         |
| Initial VO$_{2\text{max}}$ (mL·kg$^{-1}$·min$^{-1}$)                    | 18.5        | 19.4                        |                                                                         |
| Hypertension | -          | -                           |                                                                         |
| Diabetes mellitus | -      | -                           |                                                                         |
| Hyperlipidemia | -       | -                           |                                                                         |
| Smoking (Current/Ex/Never)     | Never     | Never                       |                                                                         |
| Body mass index | 24.0       | 24.8                        |                                                                         |
| LVEF (%) Baseline | 49        | 25                          |                                                                         |
| LVEF (%) Post CR & discontinuation CTx | 53        | 57                          |                                                                         |
| Duration (month) Time from the start of CR | 9         | 7                           |                                                                         |
| CTx-Monoclonal antibody | +        | +                           |                                                                         |
| CTx-Taxanes | +          | +                           |                                                                         |
| CTx-Doxorubicin, cyclophosphamide | -     | +                           |                                                                         |
| CTx-Tamoxifen | -       | -                           |                                                                         |

VO$_{2\text{max}}$: Maximal oxygen consumption; LVEF: Left ventricular ejection fraction; CTx: Chemotherapy; CR: Cardiac rehabilitation.

| TABLE 2                                                                 |
| Outcome variables before and after cardiac rehabilitation               |
| Variables                                                              | Case 1 | Case 2 |
|-------------------------------------------------------------------------|--------|--------|
| VO$_{2\text{max}}$ (mL·kg$^{-1}$·min$^{-1}$) Baseline                   | 18.5   | 19.4   |
| 8-weeks later                                                          | 24.2   | 30.3   |
| Rate of change (%)                                                     | +30.8  | +56.1  |
| Double product (mmHg·beat·min$^{-1}$) Baseline                         | 18.669 | 17.280 |
| 8-weeks later                                                          | 16.560 | 13.452 |
| VE/VCO$_2$ slope Baseline                                              | 27.6   | 36.1   |
| 8-weeks later                                                          | 29.9   | 22.3   |
| HR$_{\text{max}}$ (beat/min) Baseline                                  | 150    | 162    |
| 8-weeks later                                                          | 171    | 176    |
| HR$_{\text{rest}}$ (beat/min) Baseline                                 | 86     | 83     |
| 8-weeks later                                                          | 70     | 66     |
| RPE$_{\text{stage3}}$ Baseline                                        | 13     | 11     |
| 8-weeks later                                                          | 11     | 9      |
| RER at VO$_{2\text{max}}$ Baseline                                    | 1.1    | 1.06   |
| 8-weeks later                                                          | 1.08   | 1.32   |

VO$_{2\text{max}}$: Maximal oxygen consumption; VE/VCO$_2$ slope: Minute ventilation/carbon dioxide production slope; HR$_{\text{max}}$: Maximal heart rate; HR$_{\text{rest}}$: Resting heart rate; RPE$_{\text{stage3}}$: Rate of perceived exertion at stage 3; RER: Respiratory exchange ratio.
(FEV1), maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP), and peak cough flow (PCF). Spirometry was performed with a VMAX 22 spirometer (Sensormedics, Yorba Linda, California, USA) used in the sitting position. Peak cough flow was assessed using an Asthma Mentor Peak flow meter (Respironics, Murrysville, PA, USA).[11]

For patients’ safety, all possible adverse effects, such as musculoskeletal problems, asymptomatic cardiac rhythms, asymptomatic HR, and blood pressure changes during rehabilitation training, were investigated.

Case 1- A 46-year-old female patient who had undergone conservation surgery for cancer of the left breast in 2009 was referred to our CR clinic for CRC on January 4, 2019. Prior to the referral, the patient was treated with palliative chemotherapy consisting of intravenous pertuzumab, trastuzumab, and docetaxel at the oncology department after diagnosis of recurrent breast cancer with lung and neck lymph node metastases in 2017. After 13 cycles of chemotherapy, concluded in July 2018, echocardiography revealed LVEF of 49%. When the patient was first referred to the CR clinic, the patient was classified as New York Heart Association (NYHA) class II, Eastern Cooperative Oncology Group performance status (ECOG PS) 1. The patient was given an individual exercise prescription after CPET and underwent HIIT three times a week for eight weeks without significant cardiovascular complications. After eight weeks of HIIT, the patient’s VO2max increased from 19.4 to 30.3 mL/kg/min (+56.1%), and 6MWD increased from 592 to 830 m (+40.2%). In addition, LVEF increased from 25 to 57% over eight months, inclusive of the CR period. A pulmonary function test revealed that FVC increased from 1.65 to 2.10 L (+27.2%), and FEV1 from 1.44 to 1.97 L (+36.8%). Furthermore, MIP increased from 62 cm H2O to 74 cm H2O (+19.3%), MEP from 62 cm H2O to 89 cm H2O (+43.5%), and PCF from 300 to 350 L/min (+16.6%). The right-hand grip power increased from 23.4 kg to 25.8 kg, and the left from 21.9 kg to 24.5 kg.

Case 2- A 53-year-old female patient who had undergone conservation surgery for cancer of the left breast in 2015 and had subsequently received oral tamoxifen, radiation therapy, and a total of six cycles of chemotherapy was referred to our CR clinic on April 23, 2019. Prior to the referral, the patient also underwent a left simple mastectomy for recurrent breast cancer in August 2018 and was prescribed intravenous paclitaxel, doxorubicin, cyclophosphamide, and trastuzumab in September 2018 at the breast surgery department. The patient complained of dyspnea upon exertion on April 4, 2019. Echocardiography, conducted on April 19, 2019, revealed an LVEF of 25% with global hyperkinesia, and chemotherapy, including trastuzumab, was discontinued. At the time of the referral, the patient was classified as NYHA class II, ECOG PS 1. The patient underwent HIIT three times a week for eight weeks without significant cardiovascular complications. After eight weeks of HIIT, the patient’s VO2max increased from 19.4 to 30.3 mL/kg/min (+56.1%), and 6MWD increased from 592 to 830 m (+40.2%). In addition, LVEF increased from 25 to 57% over eight months, inclusive of the CR period. A pulmonary function test revealed that FVC increased from 1.65 to 2.10 L (+27.2%), and FEV1 from 1.44 to 1.97 L (+36.8%). Furthermore, MIP increased from 62 cm H2O to 74 cm H2O (+19.3%), MEP from 62 cm H2O to 89 cm H2O (+43.5%), and PCF from 300 to 350 L/min (+16.6%). The right-hand grip power increased from 23.4 kg to 25.8 kg, and the left from 21.9 kg to 24.5 kg.

DISCUSSION

This is a case report on CR using a HIIT protocol in patients with CRC in which the maximal oxygen consumption, maximal HR, pulmonary function, and peripheral and respiratory muscle strength were compared before and after CR. In both cases, the overall exercise capacity improved after eight weeks of the program, with increases in VO2max, 6MWD, and LVEF (Figure 1). Moreover, no major cardiovascular or other musculoskeletal complications arose during CR.

Recent trials have suggested that oxygen consumption in patients with coronary artery disease improves by 11-25% after CR.[12] In addition, as CR protocols, HIIT has shown a relatively low rate of

![Figure 1. Change in exercise capacity after cardiac rehabilitation](image)

VO2max: Maximal oxygen consumption; LVEF: Left ventricular ejection fraction; CR: Cardiac rehabilitation.
significant cardiovascular complications compared with low-to moderate-intensity continuous exercise training for patients with coronary artery disease or HF.\[13\] Considering that HIIT objectively improved VO2max by up to 56.1% without any significant cardiovascular events in this case report, this could be a noteworthy change. Furthermore, considerations need to be made for the different pathophysiology of CRC compared to coronary artery disease, and that CRC is related to reversible changes in the heart after the discontinuation of chemotherapy. Initiation of standard HF treatment and discontinuation of cardiotoxic agents enhances left ventricular functional recovery.\[4\] In this case report, the improvements in cardiac function were highly associated with drug discontinuation, whereas the HIIT program led to increases in aerobic exercise capacity, pulmonary function, and skeletal and respiratory muscle strength. Additionally, as VO2max is a powerful predictor of all-cause cardiac mortality in HF, CR with HIIT could be recommended in patients with CRC.\[6,9\]

The mortality of cancer survivors with cardiomyopathy is significantly higher than that of patients with idiopathic nonischemic cardiomyopathy.\[11\] The importance of this problem was highlighted in a cohort study published in 2011, which demonstrated that cardiovascular disease is a greater cause of mortality in breast cancer survivors than recurrent malignant diseases.\[14\] On the prophylactic side, blood pressure control, healthy diet, smoking cessation, and moderate aerobic exercise are significant nonpharmacological strategies to prevent chemotherapy-induced cardiotoxicity.\[15\] Furthermore, it is necessary to monitor the occurrence of HF during chemotherapy to discontinue and change the drug after early diagnosis and prescribe a CR program in the future, particularly in breast cancer patients.

In conclusion, HIIT could be used as a safe and efficient CR protocol in CRC patients; however, the small number of patients enrolled makes it difficult to provide definitive conclusions. Therefore, large-scale multicenter randomized studies are required to confirm the long-term effectiveness and safety of HIIT in patients with CRC.

**Patient Consent for Publication:** Written informed consent was obtained from both patients for the publication of their cases.

**Data Sharing Statement:** The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Author Contributions:** Conceptualization: C.H.E., K.C.; Data curation: K.M.J.; Investigation: C.H.E., P.J.H.; Methodology: C.H.E.; Writing - original draft: P.J.H.; Writing - review & editing: C.H.E., K.C., K.M.J.

**Conflict of Interest:** The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

**Funding:** This work was supported by the national research foundation (NRF) 2019RIG1A1004676.

**REFERENCES**

1. Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, et al. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: A scientific statement from the American Heart Association. Circulation 2019;139:e997-e1012.
2. Koutsoukis A, Ntalianis A, Repasos E, Kastritis E, Dimopoulos MA, Paraskevaidis I. Cardio-oncology: A focus on cardiotoxicity. Eur Cardiol 2018;13:64-9.
3. Westphal JG, Schulze PC. Exercise training in cancer related cardiomyopathy. J Thorac Dis 2018;10(3 Suppl 3):S4391-S4399.
4. Florescu M, Cinteza M, Vinereanu D. Chemotherapy-induced cardiotoxicity. Maedica (Bucur) 2013:8:59-67.
5. Nolan MT, Lowenthal RM, Venn A, Marwick TH. Chemotherapy-related cardiomyopathy: A neglected aspect of cancer survivorship. Intern Med J 2014;44:939-50.
6. Dalal HM, Doherty P, Taylor RS. Cardiac rehabilitation. BMJ 2015;351:h5000.
7. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2017;35:893-911.
8. Cavarretta E, Mastroiacovo G, Lupieri A, Frati G, Peruzzi M. The positive effects of exercise in chemotherapy-related cardiomyopathy. Adv Exp Med Biol 2017:1000:103-29.
9. Lin MT, Chen WC, Wu CH, Chen SY, Lee CM. The effectiveness of cardiac rehabilitation in non-ischemic dilated cardiomyopathy patients: A pilot study. J Formos Med Assoc 2020;119:627-34.
10. Lan C, Chen SY, Hsu CJ, Chiu SF, Lai JS. Improvement of cardiorespiratory function after percutaneous transluminal coronary angioplasty or coronary artery bypass grafting. Am J Phys Med Rehabil 2002;81:336-41.
11. Graham BL, Steenbruggen J, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med 2019;200:e70-e88.
12. Dun Y, Smith JR, Liu S, Olson TP. High-intensity interval training in cardiac rehabilitation. Clin Geriatr Med 2019;35:469-87.
13. Weewege MA, Ahn D, Yu J, Liou K, Keech A. High-intensity interval training for patients with cardiovascular disease-is it safe? A systematic review. J Am Heart Assoc 2018;7:e009305.
14. Patnaik JL, Byers T, DiGiuseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: A retrospective cohort study. Breast Cancer Res 2011;13:R64.

15. Avila MS, Siqueira SRR, Ferreira SMA, Bocchi EA. Prevention and treatment of chemotherapy-induced cardiotoxicity. Methodist Debakey Cardiovasc J 2019;15:267-73.